
    
      Atezolizumab will be given on day 1 of a 21-day cycle at 1200 mg IV. Radiographic assessments
      for disease response will occur every 6 weeks while on treatment. Confirmatory scans should
      be obtained â‰¥ 4 weeks following initial documentation of objective response or progressive
      disease on atezolizumab therapy.

      Atezolizumab will be given as long as the patient continues to experience clinical benefit in
      the opinion of the investigator or until unacceptable toxicity, symptomatic deterioration
      attributed to disease progression.

      Patients will be followed for 12 months or until death as per standard of care after
      discontinuation of Atezolizumab or until death, whichever occurs first.
    
  